Garren Hideki's Insider Trades & SAST Disclosures
Garren Hideki's most recent trade in Prothena Corporation plc was a trade of 85,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 27, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Garren Hideki.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prothena Corporation plc | Garren Hideki | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Coya Therapeutics Inc | Garren Hideki | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.90 per share. | 16 Aug 2023 | 2,000 | 2,000 (0%) | 0% | 24.9 | 49,800 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2023 | 2,000 | 194,000 | - | - | Stock Option (Right to Buy) | |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 58.15 per share. | 16 Aug 2023 | 878 | 1,122 (0%) | 0% | 58.2 | 51,059 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 58.93 per share. | 16 Aug 2023 | 748 | 374 (0%) | 0% | 58.9 | 44,079 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 59.74 per share. | 16 Aug 2023 | 374 | 0 (0%) | 0% | 59.7 | 22,341 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.90 per share. | 12 Jul 2023 | 2,000 | 2,000 (0%) | 0% | 24.9 | 49,800 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2023 | 2,000 | 196,000 | - | - | Stock Option (Right to Buy) | |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 67.48 per share. | 12 Jul 2023 | 1,908 | 92 (0%) | 0% | 67.5 | 128,753 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 68.20 per share. | 12 Jul 2023 | 92 | 0 (0%) | 0% | 68.2 | 6,274 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2023 | 12,000 | 210,000 | - | - | Stock Option (Right to Buy) | |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.90 per share. | 15 Mar 2023 | 12,000 | 12,000 (0%) | 0% | 24.9 | 298,800 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 48.66 per share. | 15 Mar 2023 | 6,000 | 0 (0%) | 0% | 48.7 | 291,970 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 48.16 per share. | 15 Mar 2023 | 6,000 | 6,000 (0%) | 0% | 48.2 | 288,966 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 48,000 | 48,000 | - | - | Stock Option (Right to Buy) | |
| Coya Therapeutics Inc | Hideki Garren | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 03 Jan 2023 | 2,000 | 2,000 | - | - | Common Stock, par value $0.0001 per share | |
| Coya Therapeutics Inc | Hideki Garren | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 03 Jan 2023 | 1,000 | 1,000 | - | - | Warrant to Purchase Common Stock | |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 4,000 | 222,000 | - | - | Stock Option (Right to Buy) | |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.90 per share. | 01 Dec 2022 | 4,000 | 4,000 (0%) | 0% | 24.9 | 99,600 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 62.51 per share. | 01 Dec 2022 | 4,000 | 0 (0%) | 0% | 62.5 | 250,040 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 4,000 | 226,000 | - | - | Stock Option (Right to Buy) | |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.90 per share. | 01 Nov 2022 | 4,000 | 4,000 (0%) | 0% | 24.9 | 99,600 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 61.82 per share. | 01 Nov 2022 | 3,489 | 511 (0%) | 0% | 61.8 | 215,683 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 62.41 per share. | 01 Nov 2022 | 511 | 0 (0%) | 0% | 62.4 | 31,892 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 4,000 | 230,000 | - | - | Stock Option (Right to Buy) | |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.90 per share. | 03 Oct 2022 | 4,000 | 0 (0%) | 0% | 60.9 | 243,600 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.90 per share. | 03 Oct 2022 | 4,000 | 4,000 (0%) | 0% | 24.9 | 99,600 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.52 per share. | 01 Aug 2022 | 4,000 | 0 (0%) | 0% | 30.5 | 122,080 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.90 per share. | 01 Aug 2022 | 4,000 | 4,000 (0%) | 0% | 24.9 | 99,600 | Ordinary Shares, par value $0.01 per share |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2022 | 4,000 | 238,000 | - | - | Stock Option (Right to Buy) | |
| Prothena Corporation plc | Hideki Garren | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2021 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges